ArticleOncoTargets and therapy2019
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Effect ofFrontiers in pharmacology · 2025Pooled it
- Natural polysaccharides as multifunctional anti-cancer agents: structure-activity relationships, mechanisms of action, and therapeutic potential.Frontiers in immunology · 2026Review
- Polysaccharides fromNutrients · 2025Review
- Bidirectional regulation of the gut microbiome-immune axis in the immune microenvironment of colorectal cancer and targeted interventions.World journal of gastrointestinal oncology · 2025Review
- STK32C as a Therapeutic Target in Colorectal Cancer via HSP90-PI3K/AKT/mTOR Signaling.International journal of biological sciences · 2025Article
- Chinese herbal medicine for the treatment of intestinal cancer: preclinical studies and potential clinical applications.Molecular cancer · 2024Review
- The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment.Molecules (Basel, Switzerland) · 2024Review
- Polysaccharide fromInternational journal of molecular sciences · 2024Article
- m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon.Frontiers in immunology · 2024Review
- Research Progress on the Anticancer Activity of Plant Polysaccharides.Recent patents on anti-cancer drug discovery · 2024Review
- Polysaccharides from Chinese herbs as natural weapons against colorectal cancer.Bioscience reports · 2023Review
- Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.Frontiers in pharmacology · 2023Review
- Therapeutic approaches to colorectal cancerFrontiers in microbiology · 2022Review
- Polysaccharides fromEvidence-based complementary and alternative medicine : eCAM · 2022Review
- The chemistry and efficacy benefits of polysaccharides fromFrontiers in pharmacology · 2022Review
- Article
- Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patientsWorld journal of gastroenterology · 2020Article
Corrections and comments
- Retracted
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been well-recognized that the polysaccharides from
aimOur research aimed to evaluate the anti-cancer effects of PAM on colorectal cancer (CRC).
methodsWe tested the effects of PAM on the growth and proliferation of CRC cells and macrophages by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The pro-inflammatory cytokines expression and secretion was analyzed by real-time RT-PCR and ELISA assay. We also used MC38 cells xenograft model to test the anti-cancer effects of PAM in vivo.
resultsWe found that although PAM treatment did not significantly affect the growth of CRC cells or enhance the proliferation of bone marrow-derived macrophages (BMDMs), it could enhance the phagocytosis of BMDMs by CRC cells. Biochemical tests and immunoblotting assays revealed that exposing BMDMs to PAM promoted the production of interleukin-6 (IL-6), interferon λ (IFN λ), tumor necrosis factor α (TNF-α), and nitric oxide (NO) through the MyD88/TLR4-dependent signaling pathway. One noteworthy observation is that PAM treatment could significantly prevent tumorigenesis of MC38 cells in C57BL/6J mice and increase the survival duration of mice with tumors, without influence on the weight of those mice. However, the anti-cancer effects of PAM were compromised in TLR4 KO mice, further suggesting that TLR4 signaling plays a vital role in the anti-cancer effects of PAM.
conclusionTherefore, PAM may prove to be a potential candidate in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.